Article Figures & Tables
Figures
Figure 1: Projected change in the prevalence of HIV (top) and hepatitis C virus (bottom) infection among injection drug users in Vancouver with and without the supervised injection facility.
Figure 2: Incremental cost-effectiveness of the supervised injection facility at different assumptions about the number of annual injections. The model shows cost savings and improved health benefits if the number of annual injections is between 490 and 1762. The base assumption is indicated by the dotted line.
Figure 3: Incremental cost-effectiveness of the supervised injection facility at different assumptions about the percentage of injection drug users who are regular users of the facility. The solid line indicates the cost-effectiveness when decreases in needle sharing are considered the only effect of the facility. The dashed line indicates the cost-effectiveness when all effects are considered (decreased needle sharing, safer injection practices [e.g., use of bleach to sterilize shared needles] and increased referral to methadone maintenance treatment). The base assumption was 21% (not shown).